CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction Association Between Living in Food Deserts and Cardiovascular Risk 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity Mode of Death in Heart Failure With Preserved Ejection Fraction

Review ArticleVolume 76, Issue 4, July 2020

JOURNAL:J Am Coll Cardiol. Article Link

Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review

G Marquis-Gravel, DJ Moliterno, SG Goodman et al. Keywords: PCI; trail design; SCAD

ABSTRACT

The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.